Silusyne e

Download as pdf or txt
Download as pdf or txt
You are on page 1of 2

silusyne

New molecular mechanism for the


persistent problem of cellulite

Novel delivery system for


microemulsified peptides

anti-cellulite
slimming

Reduces adipogenesis
by decreasing PGC-1

Flattens the dermohypodermal junction

Description

Science

Active ingredient that reduces adipocyte


differentiation
by
decreasing
Peroxisome
proliferator-activated receptor Gamma Coactivator 1 (PGC-1) expression. An impaired
adipocyte maturation rate results in a lower lipid
accumulation in the adipose tissue. silusyne
diminishes irregularities on skin surface due to a
reduction of fat nodules responsible for cellulite

Cellulite is a persistent problem in modern society


and it appears due to several factors such as
genetics or gender but also because of unhealthy
lifestyles. Visible fat nodules are a consequence
of an increase in adipocyte volume and number
that leads to greater fat depots that distort the
connective tissue, affecting the lymphatic drainage
system as well. Therefore, waste materials cannot
be removed and, together with collagen fibres,
create an immobile network where fat cells are
trapped. As a result, the dermo-hypodermal
junction line becomes more irregular and cellulite
manifests on skin surface.
PGC-1 is a transcriptional coactivator that interacts
with the Peroxisome Proliferator-activated Receptor
PPAR. PGC-1 is involved in adipogenesis and by
modulating its expression, adipocyte maturation
rate can be regulated.
silusyne is a peptide in a new and specific delivery
system that decreases preadipocyte differentiation
and hence lipid accumulation in the adipose tissue
by reducing PGC-1 expression.

Appearance
Suspension containing 0.05% active ingredient.

INCI
Water (Aqua), Soybean (Glycine Soja) Oil,
Propanediol, Sorbitan Sesquioleate, Isohexadecane,
Hydroxypropyl Starch Phosphate, Sclerotium Gum,
Sodium Hyaluronate, Lauryldimonium Hydroxypropyl
Hydrolyzed Soy Protein, Acetyl Hexapeptide-39.
Paraben free.

Properties
silusyne reduces adipogenesis by decreasing
PGC-1 expression. This new ingredient helps
to improve the appearance of visible cellulite as
dermo-hypodermal junction irregularities are
smoothed.

Dosage 2%

Applications
silusyne is a perfect ingredient for anti-cellulite
and slimming treatments and as a complement in
any type of body care formulations.

Solubility
Dispersible in water.

www.lipotec.com

silusyne

In vitro efficacy
1. EFFECT ON PGC-1 EXPRESSION

Human preadipocytes were incubated in a growth medium and differentiated with


Preadipocyte Differentiation Medium (PDM-2) in presence of silusyne. After 10 days, cells
were lysed, RNA was extracted and reverse transcription was performed. The resulting cDNA
was analysed by quantitative RT-PCR.

36.5%

di No
ffe nre tre
nt at
ia ed
te n
d o
ce nlls
di
ffe
re No
nt n
ia -tr
te ea
d te
A
ce d
ce
lls
ty
lH
ex
ap
e
(2 ptid
5 e
A
g/ -39
ce
m
ty
l)
lH
ex
ap
(1 ept
00 id
g e/m 39
l)

Relative quantity of
PGC-1 mRNA (%)

16.7%

silusyne reduced the


expression of PGC-1
by more than 36%

2. EFFECT ON LIPID ACCUMULATION


silusyne was added to human preadipocytes differentiated with Preadipocyte Differentiation
Medium (PDM-2). After 10 days, levels of intracellular lipid droplets were measured by
fluorescence.
45.8%

67.2%

di No
ffe nre tre
nt at
ia ed
te n
d o
ce nlls
di
ffe
N
re o
nt n
ia -tr
te ea
d te
Ca
ce d
ffe
lls
in
e
(2
00
g
A
/m
ce
ty
l)
lH
ex
ap
e
(2 ptid
A
5 e
ce
g/ -39
ty
m
lH
l)
ex
ap
(1 ept
00 id
g e/m 39
l)

Lipid accumulation (%)

29.9%

Cells treated
with silusyne
shows lower lipid
accumulation
than cells treated
with caffeine

In vivo efficacy
EVALUATION OF DERMO-HYPODERMAL JUNCTION

Dermo-hypodermal junction
line decrease (mm)

In order to study the efficacy of silusyne as an anti-cellulite and slimming ingredient, a decrease
in length of the dermo-hypodermal junction was measured. This represents an improvement of
the cutaneous and subcutaneous tissue uniformity.
20 female volunteers (aged 25 to 45) applied a cream containing 2% silusyne on one thigh and
a placebo cream on the other twice a day for 3 weeks.
An ultrasound ecograph in B-scan mode (Ultrasound Scanner Dermascan C) was used to
measure the length of the dermo-hypodermal junction line.

Skin surface is improved


with silusyne

silusyne enhanced the


uniformity of the skin by
21% after 3 weeks and
5-fold versus placebo.

21%

0 weeks

3 weeks

While the claims and supporting data provided in this publication are believed to be reliable and they are presented free and for guidance only, there are no warranties of any kind. All express and
implied warranties are disclaimed. The recipient is solely responsible for ensuring that products marketed to consumers comply with all relevant laws and regulation. LIPOTEC is the exclusive holder
of the both industrial and intellectual property rights identified herein. Recipient of this publication agrees to indemnify and hold harmless each entity of the LIPOTEC organization for any and all
regulatory action arising from recipients use of any claims or information in this publication, including, but not limited to, use in advertising and finished product label claims, and not present this
publication as evidence of finished product claim substantiation to any regulatory authority.

Isaac Peral 17 Pol. Industrial Cam Ral - 08850 Gav (Barcelona) Spain-Tel +34 93 638 80 00 / Fax +34 93 638 93 93 - [email protected]

Ed. 11A

You might also like